HER2 Support Group Forums - View Single Post

Aussie Girl · 02-09-2014, 03:21 AM

First two links are example of in vitro data:

http://www.ncbi.nlm.nih.gov/pubmed/14977844

http://jme.endocrinology-journals.or.../41/5/367.full

Third link with key info about Tamoxifen and Herceptin
http://www.obgyn.net/breast-health/s...-breast-cancer

Trastuzumab Plus Hormones
Estrogen receptor (ER) biochemistry is complex due to multiple ligand/receptor species, interactions with signal transduction pathways, and interactions with transcriptional co-activators and co-repressors. Patients who are both ER+ and HER2 overexpressors may respond less well to tamoxifen, and the time to progression is shortened.17 Combined receptor blockade with antiestrogens and trastuzumab is a rational intervention approach, and a phase II trial of tamoxifen plus trastuzumab as first-line therapy for ER+ metastatic breast cancer is in progress. A similar comparative trial including the aromatase inhibitor anastrozole and the combination of letrozole plus trastuzumab in tamoxifen-resistant HER2 and ER+ and/or PR+ breast cancer is also planned.

Fourth Link is ESMO
http://annonc.oxfordjournals.org/con...nc.mdt284.full

In general, chemotherapy should not be used concomitantly with ET [II, D] [62]. Trastuzumab may routinely be combined with non-anthracycline-based chemotherapy and ET [I, A]; concomitant use with anthracyclines is not routinely recommended outside of clinical trials, although may be considered in selected patients treated in experienced centres. For most patients, the use of a sequential anthracycline-based followed by taxane-trastuzumab- based regimen is the preferred choice. RT may be delivered safely during trastuzumab, ET and non-anthracycline-based chemotherapy [III, B].

I hope that info helps. I would still ask about Perjeta, and other drugs such as Tykerb, Kadcyla. It won't hurt to ask because her disease is quite locally advanced. It is worth getting to know a little about the weapons that may be called on later, so to speak.

The senior members on the site who are often Stage 3b to stage 4 have the best understanding of the chemo regimens. I've only joined the crew in June 2013, so I am a relative newbie.

Cheers

Aussie Girl

02-09-2014, 03:21 AM	#4
Aussie Girl Senior Member Join Date: Jul 2013 Posts: 260	Re: Really scared please help First two links are example of in vitro data: http://www.ncbi.nlm.nih.gov/pubmed/14977844 http://jme.endocrinology-journals.or.../41/5/367.full Third link with key info about Tamoxifen and Herceptin http://www.obgyn.net/breast-health/s...-breast-cancer Trastuzumab Plus Hormones Estrogen receptor (ER) biochemistry is complex due to multiple ligand/receptor species, interactions with signal transduction pathways, and interactions with transcriptional co-activators and co-repressors. Patients who are both ER+ and HER2 overexpressors may respond less well to tamoxifen, and the time to progression is shortened.17 Combined receptor blockade with antiestrogens and trastuzumab is a rational intervention approach, and a phase II trial of tamoxifen plus trastuzumab as first-line therapy for ER+ metastatic breast cancer is in progress. A similar comparative trial including the aromatase inhibitor anastrozole and the combination of letrozole plus trastuzumab in tamoxifen-resistant HER2 and ER+ and/or PR+ breast cancer is also planned. Fourth Link is ESMO http://annonc.oxfordjournals.org/con...nc.mdt284.full In general, chemotherapy should not be used concomitantly with ET [II, D] [62]. Trastuzumab may routinely be combined with non-anthracycline-based chemotherapy and ET [I, A]; concomitant use with anthracyclines is not routinely recommended outside of clinical trials, although may be considered in selected patients treated in experienced centres. For most patients, the use of a sequential anthracycline-based followed by taxane-trastuzumab- based regimen is the preferred choice. RT may be delivered safely during trastuzumab, ET and non-anthracycline-based chemotherapy [III, B]. I hope that info helps. I would still ask about Perjeta, and other drugs such as Tykerb, Kadcyla. It won't hurt to ask because her disease is quite locally advanced. It is worth getting to know a little about the weapons that may be called on later, so to speak. The senior members on the site who are often Stage 3b to stage 4 have the best understanding of the chemo regimens. I've only joined the crew in June 2013, so I am a relative newbie. Cheers Aussie Girl __________________ 31mm Infiltrating duct carcinoma Grade 3, ER/PR-, HER2+, Neg Sentinel nodes x 5 49mm field of DCIS 17 June '13: Screen detected impalpable mass, Mammogram neg, US. 25 June '13: Diagnosed after multiple biopsies and MRIs 28 June '13: Left lumpectomey 4 July '13: Left Mastectomy 12 August '13: Commenced TCH chemo Mid December '13 : TCH finished. Herceptin continuing three weekly. 4 August 2014- Herceptin infusions finished. END OF THERAPY - YAY!